share_log

NLS Pharmaceutics Analyst Ratings

NLS Pharmaceutics Analyst Ratings

NLS 藥劑學分析師評級
Benzinga Analyst Ratings ·  2022/12/08 21:42
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
12/08/2022 352.08% Maxim Group → $4 Upgrades Hold → Buy
11/08/2022 — Maxim Group Downgrades Buy → Hold
09/06/2022 578.12% Laidlaw & Co. → $6 Initiates Coverage On → Buy
03/12/2021 1256.24% Brookline Capital → $12 Initiates Coverage On → Buy
03/03/2021 804.16% Maxim Group → $8 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
12/08/2022 352.08% Maxim集團 → $4 升級 持有→購買
11/08/2022 — Maxim集團 評級下調 購買→Hold
09/06/2022 578.12% 萊德勞公司 → $6 開始承保 →購買
03/12/2021 1256.24% 布魯克林資本 → $12 開始承保 →購買
03/03/2021 804.16% Maxim集團 → $8 開始承保 →購買

What is the target price for NLS Pharmaceutics (NLSP)?

NLS製藥公司(NLSP)的目標價是多少？

The latest price target for NLS Pharmaceutics (NASDAQ: NLSP) was reported by Maxim Group on December 8, 2022. The analyst firm set a price target for $4.00 expecting NLSP to rise to within 12 months (a possible 352.08% upside). 3 analyst firms have reported ratings in the last year.

梅克西姆集團於2022年12月8日報道了NLS製藥公司(納斯達克代碼：NLSP)的最新目標價。這家分析公司將目標價定為4美元，預計NLSP將在12個月內上漲至(可能上漲352.08%)。3家分析公司在過去一年公佈了評級。

What is the most recent analyst rating for NLS Pharmaceutics (NLSP)?

NLS製藥公司(NLSP)的最新分析師評級是多少？

The latest analyst rating for NLS Pharmaceutics (NASDAQ: NLSP) was provided by Maxim Group, and NLS Pharmaceutics upgraded their buy rating.

新星醫藥(納斯達克代碼：NLSP)的最新分析師評級由Maxim Group提供，新星製藥上調了其買入評級。

When is the next analyst rating going to be posted or updated for NLS Pharmaceutics (NLSP)?

NLS製藥(NLSP)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NLS Pharmaceutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NLS Pharmaceutics was filed on December 8, 2022 so you should expect the next rating to be made available sometime around December 8, 2023.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與NLS製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。NLS製藥的上一次評級是在2022年12月8日提交的，所以你應該預計下一次評級將在2023年12月8日左右提供。

Is the Analyst Rating NLS Pharmaceutics (NLSP) correct?

分析師對NLS製藥公司(NLSP)的評級正確嗎？

While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a upgraded with a price target of $0.00 to $4.00. The current price NLS Pharmaceutics (NLSP) is trading at is $0.88, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的NLS製藥(NLSP)評級被上調，目標價為0.00美元至4.00美元。NLS製藥公司(NLSP)目前的交易價格為0.88美元，在分析師的預測範圍內。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論